

Marcus-Hillert Schultze-Mosgau

List of Publications by Year in Descending Order

Source:

<https://exaly.com/author-pdf/9300027/marcus-hillert-schultze-mosgau-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14
papers

143
citations

7
h-index

11
g-index

14
ext. papers

167
ext. citations

3.5
avg, IF

2.76
L-index

#	Paper	IF	Citations
14	Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021 , 1	2.7	0
13	The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive-A randomized controlled trial. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 925-936	3.8	2
12	Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. <i>Clinical Pharmacology in Drug Development</i> , 2021 , 10, 486-493	2.3	3
11	Effect of Food Intake on the Pharmacokinetics of the Selective Progesterone Receptor Modulator Vilaprisan: A Randomized Clinical Study in Healthy Postmenopausal Women. <i>Clinical Pharmacology in Drug Development</i> , 2021 , 10, 675-680	2.3	1
10	Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	3
9	Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
8	Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 1030-1038	2.9	3
7	Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2011-2021	3.8	7
6	Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1001-1015	6.2	22
5	Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 228-239	2.9	18
4	Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies. <i>ChemMedChem</i> , 2018 , 13, 2271-2280	3.7	19
3	CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2857-2866	3.8	12
2	Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women?. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017 , 55, 16-24	2	20
1	Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. <i>Human Reproduction</i> , 2016 , 31, 1703-12	5.7	32